Use of composition comprising e.g. clozapine, quetiapine, olanzapine, benzyl- and/or phenylethyl alcohol, ethanol, ethereal oil, sweetener, and polyethylene glycol, for preparing an orally administering solution to treat schizophrenia

摘要

Use of a composition (I) comprising (in mg/ml): (a) clozapine (10-200), quetiapine (25-300), acid addition salt of quetiapine (25-300) and/or olanzapine (1-20); (b) benzyl- and/or phenylethyl- alcohol (0-20); (c) propylene glycol (0-200), ethanol (up to 50) and active agent (up to 0.5 wt.%); (d) ethereal oil, flavor and/or sweetener (0-50); and (e) liquid polyethylene glycol, polyoxypropylene, poloxamer, plant oil, triglyceride, polyoxyethylated and/or polyoxypropylated fatty acid glyceride, paraffin and/or glycerin, for the preparation of a solution for oral administration, is claimed. Use of a composition comprising (in mg/ml): (a) clozapine (10-200), quetiapine (25-300), one or more hardly soluble acid addition salt of quetiapine as quetiapine base (25-300) and/or olanzapine (1-20), as active agent; (b) benzyl- and/or phenylethyl- alcohol (0-20); (c) propylene glycol (0-200), ethanol (up to 50) and active agent (up to 0.5 wt.%) of 3-4C-alkanol; (d) ethereal oil, flavor and/or sweetener (0-50); and (e) 1 ml of liquid polyethylene glycol, polyoxypropylene, poloxamer, plant oil, triglyceride, polyoxyethylated and/or polyoxypropylated fattyacid glyceride, liquid paraffin and/or glycerin, for the preparation of a solution for oral administration, is claimed; where the component (e) exhibits a peroxide content of less than 100 ppm and the amount of residual oxygen in the solution is 1 mg/ml. ACTIVITY : Neuroleptic. MECHANISM OF ACTION : None given.